10-Q: Bio-Rad Reports Q3 Loss Amid Sartorius Valuation Drop

Bio-Rad Laboratories reported a net loss for the third quarter of 2025, primarily driven by a significant decline in the fair value of its investment in Sartorius AG, despite a slight increase in net sales.

Summary

• Net sales for the third quarter of 2025 increased by 0.5% to $653.0 million compared to $649.7 million in Q3 2024, but decreased by 1.7% on a currency-neutral basis.
• For the nine months ended September 30, 2025, net sales decreased by 0.5% to $1.89 billion, or 0.7% on a currency-neutral basis, compared to the same period in 2024.
• The company recorded a net loss of $341.9 million for Q3 2025, a significant reversal from a net income of $653.2 million in Q3 2024.
• For the nine months, net income was $39.9 million, a substantial improvement from a net loss of $1,128.4 million in the prior year period.
• Gross profit margin declined to 52.6% for both the three and nine months ended September 30, 2025, from 54.8% and 54.6% respectively, in the prior year periods, primarily due to higher material costs and reduced fixed manufacturing absorption.
• Operating income for Q3 2025 was $65.3 million, slightly up from $64.5 million in Q3 2024, but for the nine months, it decreased by 21.2% to $166.1 million.
• The fair market value of equity securities and loan receivable resulted in a $495.3 million loss in Q3 2025, primarily from the Sartorius AG investment, compared to a $792.9 million gain in Q3 2024.
• Bio-Rad acquired Stilla Technologies on June 30, 2025, for $257.7 million, including $166.5 million cash and $28.6 million in contingent consideration, to strengthen its droplet digital PCR offering.
• A new restructuring plan, approved in February 2025, incurred $40.8 million in expenses for the nine months, primarily for employee termination benefits, and is expected to be substantially completed by year-end 2025.
• The company repurchased 1,205,381 Class A common shares for $295.5 million during the nine months ended September 30, 2025, with $284.6 million remaining under the 2023 Share Repurchase Program.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to declining currency-neutral sales, reduced gross margins, and a significant net loss in the most recent quarter driven by investment volatility. While the nine-month net income shows an improvement from a prior-year loss, this is largely due to a less severe investment impact rather than strong operational growth. Ongoing restructuring and persistent global economic headwinds add to the cautious outlook.

Positives

• Net income for the nine months ended September 30, 2025, improved significantly to $39.9 million from a net loss of $1,128.4 million in the prior year, primarily due to a less severe decline in the fair value of the Sartorius AG investment.
• Net cash provided by operating activities increased by 10.9% to $367.3 million for the nine months ended September 30, 2025, compared to $331.0 million in the prior year, driven by improved working capital.
• The acquisition of Stilla Technologies strengthens the company's offering in droplet digital PCR and facilitates entry into new molecular testing markets.
• The company continues to execute its share repurchase program, buying back 1,205,381 Class A shares for $295.5 million during the nine-month period, indicating confidence in its valuation and returning capital to shareholders.
• Foreign currency exchange gains, net, improved to $2.9 million in Q3 2025 from a $1.6 million loss in Q3 2024, and to $4.5 million for the nine months from $2.0 million in the prior year.

Negatives

• The company reported a net loss of $341.9 million for the third quarter of 2025, a substantial decline from a net income of $653.2 million in the same period last year.
• Net sales on a currency-neutral basis decreased by 1.7% in Q3 2025 and 0.7% for the nine months, indicating underlying business contraction.
• Consolidated gross margin decreased by 2.2 percentage points in Q3 2025 and 2.0 percentage points for the nine months, primarily due to higher material costs and reduced fixed manufacturing absorption.
• The Life Science segment's currency-neutral sales decreased by 1.5% in Q3 2025 due to a constrained academic research and biotech funding environment.
• The Clinical Diagnostics segment's currency-neutral sales decreased by 1.8% in Q3 2025, primarily driven by lower reimbursement rates for diabetes testing in China.
• Selling, general and administrative (SG&A) expenses increased by 3.2% in Q3 2025 and 2.2% for the nine months, partly due to higher employee-related and restructuring costs.
• Net cash used in investing activities increased to $155.5 million for the nine months, partly due to the Stilla acquisition.
• Net cash used in financing activities increased to $286.5 million for the nine months, primarily due to higher payments for share repurchases, reducing overall cash and cash equivalents.

Risks

• International operations expose the company to additional costs and complex legal and regulatory risks, including data privacy, labor laws, tax laws, trade restrictions, and anti-corruption laws, with potential for fines or sanctions.
• The highly competitive life science and clinical diagnostics markets, with some competitors having greater financial resources, could lead to pricing pressures and inability to recover increased costs.
• Failure to develop and introduce new or improved products in a timely manner, exacerbated by supply chain disruptions, could adversely affect business growth and lead to product obsolescence.
• Global economic and geopolitical conditions, including inflationary pressures, conflicts (Russia-Ukraine, Middle East), and moderating economic growth in China, could decrease demand, increase competition, and raise costs.
• Reductions in government funding and capital spending by customers (universities, government agencies, biopharma) continue to negatively impact revenue.
• A reduction or interruption in the supply of components and raw materials, including reliance on sole suppliers, could adversely affect manufacturing operations and product sales.
• Breaches of information systems, including cyberattacks, phishing, and fraud schemes, could lead to misappropriation of confidential information, operational disruptions, and financial losses.
• Disruptions to IT systems or failure to successfully implement and integrate new systems could harm business operations and financial condition.
• Foreign currency exchange fluctuations can materially impact results, with a strengthening U.S. dollar negatively affecting international sales and a weakening dollar increasing international expenses.
• Changes in the market value of the investment in Sartorius AG materially impact financial results, with declines leading to significant losses and potential share price volatility.
• The company's significant investment in Sartorius AG could potentially lead to being deemed an investment company under the Investment Company Act of 1940, which would have a material adverse effect.
• Incurring losses due to write-downs in the value of financial instruments, including asset-backed securities and the collateralized loan to SHB, due to market volatility or debtor financial conditions.
• Recent and planned changes to the organizational structure, including restructurings, could lead to unintended consequences such as management distraction, labor unrest, workforce attrition, and reduced morale.
• Risks related to intellectual property rights, including challenges, invalidation, infringement claims, and the inability to license protected technology, could negatively impact the business.
• Changes in the healthcare industry, such as managed care trends, consolidation among providers, and reduced third-party reimbursements (e.g., Medicare CLFS, PAMA, diabetes testing in China), could adversely affect the Clinical Diagnostics business.
• Substantial government regulation (FDA, EU IVDR, foreign counterparts) and potential changes or violations could lead to penalties, product recalls, or restrictions on marketing and sales.
• Inability to successfully integrate acquired companies, products, or technologies, or failure to realize anticipated benefits from acquisitions, could lead to contingent liabilities or impairment charges.
• Product quality and liability issues, including defects in design or manufacturing, could harm reputation, customer relationships, and financial performance.
• Lack of key personnel, intense competition for qualified professionals, and challenges in management transitions could hurt the business.
• Higher than anticipated tax liabilities due to differing interpretations of tax laws, audits, changes in tax laws (e.g., OBBBA, Inflation Reduction Act), or international tax frameworks (OECD BEPS Pillar Two).
• Environmental, health, and safety regulations, including increasing focus on ESG matters, could result in significant compliance costs, fines, and reputational damage.
• The use of generative AI and other AI technologies presents risks related to evolving regulations, data protection, intellectual property infringement, and the generation of false or misleading outputs.
• Substantial debt and related covenants may restrict future operations, limit financial flexibility, and increase vulnerability to adverse economic conditions.
• The Schwartz family's significant majority voting stock ownership could lead to conflicts of interest and delay or prevent a change in control.
• The forum selection provision in bylaws could increase costs or limit stockholders' ability to bring claims in preferred judicial forums.

Future Outlook

The company expects uncertain global economic and geopolitical conditions, including inflationary pressures, and moderating economic growth in China, to continue negatively impacting its business through the rest of 2025. Reductions in government funding and ongoing challenges in the biopharma market and among small biotech companies are also expected to persist. The February 2025 restructuring plan is anticipated to be substantially completed by the end of 2025.

Management Comments

• Current global economic and geopolitical conditions remain uncertain, and we rely on the support of many governments for both research and healthcare.
• Reduced government spending, along with ongoing challenges in the biopharma market and among small biotech companies, continues to negatively impact our business.
• The market in China, which represents a mid-single digit percentage of our year-to-date 2025 consolidated net sales, remains uncertain as a result of these factors.
• We expect these conditions to continue through the rest of 2025.
• Management believes that our cash, cash equivalents and short-term investments, together with cash flow from operations and the Revolving Credit Agreement will be adequate to meet our current objectives for operations, research and development, capital additions for manufacturing and distribution, plant and equipment, information technology systems and acquisitions of reasonable proportion to our existing total available capital for the next twelve months and beyond.

Industry Context

The life science and clinical diagnostics markets remain highly competitive, with some competitors possessing greater financial resources. The industry is facing challenges from reduced government funding, ongoing difficulties in the biopharma market, and pressures on small biotech companies. Healthcare industry changes, including managed care trends, consolidation among providers, and reduced third-party reimbursements (especially for diabetes testing in China), continue to impact the Clinical Diagnostics segment. The regulatory landscape is also evolving, with new rules like the EU IVDR requiring product modifications and stricter regulations emerging in countries like Russia, China, Brazil, and India. The company's strategic acquisition of Stilla Technologies aims to strengthen its position in the growing droplet digital PCR market, aligning with the industry's focus on advanced molecular testing applications.

Comparison to Industry Standards

• The decline in currency-neutral sales across both Life Science (-1.5% in Q3) and Clinical Diagnostics (-1.8% in Q3) segments suggests that Bio-Rad is experiencing headwinds similar to or potentially more pronounced than broader industry trends, which are generally characterized by constrained academic research and biotech funding, and lower reimbursement rates in key markets like China.
• The decrease in gross margin for both segments (Life Science -1.7 ppt, Clinical Diagnostics -2.5 ppt in Q3) indicates that Bio-Rad is facing challenges with higher material costs and reduced fixed manufacturing absorption, which could be a sector-wide issue or specific to its operational efficiencies compared to peers.
• The significant volatility in net income driven by the fair value changes of the Sartorius AG investment is a unique factor for Bio-Rad, distinguishing its reported bottom-line performance from companies focused purely on operational results in the life science and diagnostics sectors.
• The ongoing restructuring efforts, including position eliminations and function consolidations, suggest the company is actively responding to cost pressures and market shifts, a common strategy among mature companies in competitive industries to optimize operational performance.

Legal Proceedings

• The company is a party to various claims, legal actions, and complaints arising in the ordinary course of business.
• Management does not believe, at this time, that any ultimate liability from these matters will have a material adverse effect on results of operations, financial position, or liquidity, but cannot give assurance regarding the ultimate outcome.

Related Party Transactions

• The company extended a collateralized loan of 400 million Euros to Sartorius-Herbst Beteiligungen II GmbH (SHB) in November 2021, due January 31, 2029. SHB used the proceeds to partially finance the acquisition of interests under the Sartorius family trust, in which Bio-Rad has a significant equity investment.

Stakeholder Impact

• Shareholders: Experience significant volatility in net income and EPS due to fair value changes in the Sartorius AG investment. Benefit from ongoing share repurchase programs. Subject to potential conflicts of interest due to Schwartz family's majority voting control.
• Employees: Directly impacted by the February 2025 restructuring plan, which includes position eliminations, function consolidations, and relocations.
• Customers: May face continued impact from reduced government funding, challenges in the biopharma market, and lower reimbursement rates in clinical diagnostics, potentially affecting demand for Bio-Rad's products.
• Suppliers: May be affected by global economic conditions, supply chain disruptions, and raw material cost increases, which could impact their ability to provide components and materials to Bio-Rad.
• Creditors: Subject to the company's substantial debt ($1.2 billion Senior Notes) and compliance with debt covenants, which could affect the company's financial flexibility.

Next Steps

• Substantially complete the February 2025 restructuring plan by the end of 2025.
• Continue to monitor global economic and geopolitical conditions, biopharma market challenges, and government funding impacts.
• Evaluate the method of adoption and effect of ASU 2023-09 (Income Tax Disclosures) for fiscal years beginning after December 15, 2024.
• Monitor SEC developments and evaluate the final rule for climate-related disclosures.
• Evaluate the effect of adopting ASU 2024-03 (Expense Disaggregation Disclosures) for annual reporting periods beginning after December 15, 2026.
• Evaluate whether to apply the practical expedient in ASU 2025-05 (Credit Losses for Accounts Receivable) for interim and annual reports beginning after December 15, 2025.
• Evaluate the impact and method of adoption for ASU 2025-05 (Internal-Use Software) for annual reporting periods beginning after December 15, 2027.
• Continue to manage foreign exchange risk through forward foreign exchange contracts.

Key Dates

Recommendation

While Bio-Rad's nine-month net income shows a significant improvement from the prior year, this is largely attributable to a less severe decline in the fair value of its Sartorius AG investment, rather than robust operational growth. The core business faces headwinds, evidenced by declining currency-neutral sales and reduced gross margins. The Q3 net loss highlights the continued volatility from the Sartorius investment. The ongoing restructuring and strategic acquisition of Stilla Technologies are positive long-term moves, but the immediate operational challenges, global economic uncertainties, and regulatory pressures warrant a cautious stance. A 'hold' recommendation reflects the mixed financial performance and the significant non-operating factors influencing the bottom line, suggesting investors monitor the execution of restructuring, integration of Stilla, and the stability of the Sartorius investment.

Keywords

Life Science, Clinical Diagnostics, SEC Filing, 10-Q, Financial Results, Sartorius AG, Acquisition, Stilla Technologies, Restructuring, Share Repurchase, Gross Margin, Net Income, Operating Income, EPS, Cash Flow, Debt, International Operations, Supply Chain, Regulatory Risk, Healthcare Industry, Biotech Funding, AI Technology, Corporate Governance